2022 American Transplant Congress
Desensitization Protocol to Prevent Severe Oliguric Antibody-Mediated Rejection
1Tokyo Womens, Tokyo 162-8666, Japan, 2Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Antibody-mediated rejection in a case with a positive crossmatch test can be severe and result in sudden onset of oliguria and sometimes, anuria, leading…2022 American Transplant Congress
Pre-Emptive Rituximab Use for Epstein-Barr Virus (EBV) Viremia in Cardiothoracic Solid Organ Transplant Recipients
University of Chicago Medicine, Chicago, IL
*Purpose: EBV viremia is associated with potentially life-threatening post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. The utility of rituximab for treating EBV viremia in…2022 American Transplant Congress
Validation of Donor Specific Antibody Characteristics Associated with Deleterious Outcomes: A Single Center Study of 940 Kidney Allograft Recipients
*Purpose: A reproducibility crisis is pervasive in scientific literature. We aimed to investigate whether the DSA characteristics we previously associated with antibody mediated rejection (AMR)…2022 American Transplant Congress
The Addition of Bortezomib to a Rituximab Based Antibody Mediated Rejection Treatment Protocol in Lung Transplant
Loyola University Medical Center, Maywood, IL
*Purpose: To evaluate the impact of antibody mediated rejection (AMR) treatment with rituximab combined with bortezomib vs. rituximab alone on patient survival, graft survival, and…2021 American Transplant Congress
Dissecting the Intrarenal Immune Response to Viral Infected Cells in Pediatric BK Virus-associated Nephropathy (BKVAN)
*Purpose: BKVAN is not only a cause of acute renal allograft injury but is a recognized cause of chronic allograft disease and in some patients,…2021 American Transplant Congress
Impact of Rituximab Induction Therapy on Donor-specific Anti-HLA Antibodies in Abo-compatible Kidney Transplant Recipients
*Purpose: Development of de novo donor-specific anti-HLA antibodies (dnDSA) after kidney transplantation remains strongly associated with antibody-mediated rejection (AMR), which leads to poor graft outcome.…2020 American Transplant Congress
B Cell Depletion with Anti-CD20 mAb Exacerbates Anti-Donor CD4+ T Cell Responses in Highly Sensitized Transplant Model
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen antibodies (DSAs) have been associated with detrimental effects in transplant recipients. To eliminate preformed DSAs, we desensitized DSA-positive recipients…2020 American Transplant Congress
T and B Lymphocyte Dynamics after Genetically-Modified Pig-To-Baboon Kidney Xenotransplantation with an Anti-CD40mAb-Based Immunosuppressive Regimen
1Surgery, University of Alabama at birmingham, Birmingham, AL, 2Revivicor, Blacksburg, VA, VA
*Purpose: We have evaluated recovery of T and B lymphocytes and their subsets after depletion by anti-thymocyte globulin (ATG) and an anti-CD20mAb (Rituximab), followed by…2020 American Transplant Congress
Rapid Preparation to Undergo ABO-Incompatible Living Donor Liver Transplantation for Acute Liver Failure
1Chang-gung Hospital, Taoyuan, Taiwan, 2Chang-gung Hospital, Taiyuan, Taiwan
*Purpose: Acute liver failure is a life-threatening condition and urgent liver transplantation is needed to save lives. In the circumstance of deceased and ABO-compatible (ABO-C)…2020 American Transplant Congress
Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
*Purpose: Owing to limited organ availability, ABO-incompatible living kidney transplantation (ABO-ILKT) has been used extensively. Various forms of preconditioning therapies have been used alone or…
- 1
- 2
- 3
- 4
- Next Page »